ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
1차 항체 시장 규모는 최근 현저하게 확대되고 있습니다. 2024년 421억 달러로 평가되었고, 2025년에는 457억 8,000만 달러에 달할 것으로 추정되며, CAGR 8.7%로 성장이 전망되고 있습니다. 지난 수년간의 성장은 생물의학 연구에 있어서 면역측정법의 활용 확대, 만성 질환 및 감염증 발생률 증가, 단백질체학 및 유전체학 분야에서 용도 확대, 학술 기관 및 연구 기관 간 제휴 강화, 진단 검사에 있어서 항체 이용 증가 등이 요인으로 되어 있습니다.
1차 항체 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 631억 3,000만 달러에 달할 것으로 예측되며, CAGR 8.4%로 성장할 전망입니다. 예측 기간의 성장요인으로는 바이오마커를 기반으로 한 연구에 대한 주목의 고조, 임상 및 트랜스레이셔널 연구 프로그램 확대, 생명과학 및 생명공학 분야에 대한 투자 증가, 항체 개발 및 시험에서의 자동화 진전 등이 있습니다. 예측 기간 주요 동향으로는 항체 공학의 기술적 진보, 재조합 항체 생산 기술의 발전, 하이 스루풋 스크리닝 기법의 연구 개발 투자, 항체 표지 및 검출 기술 혁신, 멀티플렉스 면역 측정 플랫폼의 기술적 진보 등을 들 수 있습니다.
면역진단법의 채용 확대는 향후 수년간 1차 항체 시장의 성장을 견인할 것으로 예측됩니다. 면역진단법이란 감염증, 자가면역질환, 암과 관련된 특정 생체분자를 검출 및 정량하기 위해 항원항체 반응을 이용하는 진단 방법을 말합니다. 헬스케어 시스템 및 검사 기관이 임상 판단과 환자 결과의 향상을 도모하기 위해 보다 정확하고 신속하고 신뢰성이 높은 질환 검출법을 요구하는 중, 그 채용은 증가 경향이 있습니다. 1차 항체는 표적 항원에 특이적으로 결합함으로써 면역 진단 분석을 지원하고 단백질, 병원체, 바이오마커의 정밀한 검출 및 분석을 가능하게 합니다. 이들은 진단 정밀도 및 신뢰성을 향상시키고, 실험적 및 임상적 검사에서의 오차를 줄이며, ELISA, 웨스턴 블로팅, 면역형광법 등의 기술에 있어서 필수적인 역할을 합니다. 예를 들어 영국 정부 기관인 영국 보건 안보청(UK Health Security Agency)에 따르면 2022년 4월부터 2024년 3월까지 HIV 검사 198만 1,590건, HCV 검사 150만 2,799건, HBV 검사 118만 5,678건이 실시되었습니다. 따라서 면역진단법의 채용 확대가 1차 항체 시장의 성장을 견인하고 있습니다.
1차 항체 시장의 주요 기업은 진단 정밀도의 향상, 워크플로우 효율의 강화, 오진 리스크의 저감을 목적으로 돌연변이 특이적 항체 등의 혁신적 제품을 개발하고 있습니다. 돌연변이 특이적 항체는 광범위한 천연 항원 집단이 아니라 정의된 항원 변이체에 선택적으로 결합하도록 설계되어 임상가가 정밀하고 특정 단백질 돌연변이를 표적으로 하는 것을 허용합니다. 예를 들어, 2023년 2월에는 스위스에 본사를 둔 진단약 및 제약 기업인 F.호프만 라로슈 AG가 IDH1 R132H(MRQ 67) 토끼 모노클로날 1차 항체 및 ATRX 토끼 폴리클로날 항체를 발매했습니다. 이 제품은 IDH1 R132H 돌연변이에 대한 높은 특이성을 나타내며 BenchMark IHC/ISH 플랫폼과 호환되며 신경병리학에서 자동화 워크플로우를 지원합니다. 이러한 항체는 진단 정확도와 워크플로우 효율을 향상시키지만 개발 비용이 높고 대상 적응 범위가 좁아집니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 1차 항체 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 1차 항체 시장 : 성장률 분석
세계의 1차 항체 시장 실적 : 규모 및 성장(2019-2024년)
세계의 1차 항체 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 1차 항체 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 1차 항체 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
1차 항체
면역글로불린 G(IgG)
면역글로불린 M(IgM)
면역글로불린 A(IgA)
기타 아이소 유형
2차 항체
세계의 1차 항체 시장 : 소스별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론 항체
폴리클로날 항체
재조합 항체
세계의 1차 항체 시장 : 기술별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
효소 면역 측정법(ELISA)
웨스턴 블로팅
면역조직화학
플로우 사이토메트리
세계의 1차 항체 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
연구개발
진단약
체외 진단
포인트 오브 케어 검사
치료제
세계의 1차 항체 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
학술기관 및 연구기관
제약 및 바이오의약품 기업
임상 실험실
수탁연구기관(CRO)
세계의 1차 항체 시장 : 1차 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
마우스 1차 항체
토끼 1차 항체
염소 1차 항체
인간 1차 항체
기타 생물종 1차 항체
세계의 1차 항체 시장 : 면역글로불린 G 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역글로불린 G1 서브클래스
면역글로불린 G2 서브클래스
면역글로불린 G3 서브클래스
면역글로불린 G4 서브클래스
세계의 1차 항체 시장 : 면역글로불린 M 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오량체 면역글로불린 M
단량체 면역글로불린 M
세계의 1차 항체 시장 : 면역글로불린 A 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역글로불린 A1 서브클래스
면역글로불린 A2 서브클래스
세계의 1차 항체 시장 : 기타 아이소 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
면역글로불린 D
면역글로불린 E
세계의 1차 항체 시장 : 2차 항체 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
효소 표지 2차 항체
형광 표지 2차 항체
비오틴화 2차 항체
무표지 2차 항체
제7장 지역별 및 국가별 분석
세계의 1차 항체 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 1차 항체 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
1차 항체 시장 : 경쟁 구도
1차 항체 시장 : 기업 프로파일
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Danaher Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Fujifilm Holdings Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Agilent Technologies Inc.
Becton Dickinson And Company
Regeneron Pharmaceuticals Inc.
Bio-Techne Corporation
Bio-Rad Laboratories Inc.
Genscript Biotech Corporation
Biocytogen Co. Ltd.
Sino Biological Inc.
Cell Signaling Technology Inc.
Cusabio Biotech Co. Ltd.
Proteintech Group Inc.
Santa Cruz Biotechnology Inc.
Rockland Immunochemicals Inc.
Creative Diagnostics Inc.
Abnova Corporation
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
1차 항체 시장(2009년) : 새로운 기회를 제공하는 국가
1차 항체 시장(2009년) : 새로운 기회를 제공하는 부문
1차 항체 시장(2009년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
A primary antibody is an immunoglobulin molecule specifically designed or naturally produced by the immune system to bind directly and with high affinity to a defined antigenic epitope, enabling selective identification, quantification, or neutralization of a target molecule in a biological sample or experimental system. It is widely used in immunoassays, molecular diagnostics, and biomedical research to detect or measure specific proteins or biomolecular targets with accuracy and reliability.
The main types of primary antibody include primary antibodies, immunoglobulin G (IgG), immunoglobulin M (IgM), immunoglobulin A (IgA), other isotypes, and secondary antibodies. Primary antibodies are highly specific immunoglobulin molecules that bind directly to target antigens to allow detection, measurement, or characterization of specific proteins or biomolecules in research, diagnostic, or therapeutic settings. They are sourced from monoclonal antibodies, polyclonal antibodies, and recombinant antibodies and use technologies such as enzyme linked immunosorbent assay (ELISA), western blotting, immunohistochemistry, and flow cytometry. They are applied in research and development, diagnostics, in vitro diagnostics, point of care testing, and therapeutics, serving end users such as academic and research institutions, pharmaceutical and biopharmaceutical companies, clinical laboratories, and contract research organizations (CROs).
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The primary antibody market research report is one of a series of new reports from The Business Research Company that provides primary antibody market statistics, including primary antibody industry global market size, regional shares, competitors with a primary antibody market share, detailed primary antibody market segments, market trends and opportunities, and any further data you may need to thrive in the primary antibody industry. This primary antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The primary antibody market size has grown strongly in recent years. It will grow from $42.10 billion in 2024 to $45.78 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to rising use of immunoassays in biomedical research, increasing incidence of chronic and infectious diseases, growing applications in proteomics and genomics, increasing collaborations among academic and research institutions, and rising utilization of antibodies in diagnostic assays.
The primary antibody market size is expected to see strong growth in the next few years. It will grow to $63.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising focus on biomarker based research, expansion of clinical and translational research programs, growing investments in life sciences and biotechnology, and increasing automation in antibody development and testing. Major trends in the forecast period include technological advancements in antibody engineering, developments in recombinant antibody production, investment in research and development for high throughput screening methods, innovations in antibody labeling and detection technologies, and technological progress in multiplex immunoassay platforms.
The increasing adoption of immunodiagnostics is expected to drive the growth of the primary antibody market in the coming years. Immunodiagnostics refers to diagnostic methods that utilize antigen-antibody reactions to detect and quantify specific biomolecules linked to infections, autoimmune diseases, and cancers. Adoption is rising as healthcare systems and laboratories seek more accurate, rapid, and reliable methods of disease detection to enhance clinical decision-making and patient outcomes. Primary antibodies support immunodiagnostic assays by specifically binding to target antigens, enabling precise detection and analysis of proteins, pathogens, or biomarkers. They improve diagnostic accuracy and reliability, reduce errors in experimental and clinical testing, and are essential in techniques such as ELISA, Western blotting, and immunofluorescence. For example, in November 2024, according to the UK Health Security Agency, a UK based government agency, between April 2022 and March 2024, a total of 1,981,590 HIV tests, 1,502,799 HCV tests, and 1,185,678 HBV tests were conducted. Therefore, the growing adoption of immunodiagnostics is driving the expansion of the primary antibody market.
Major companies in the primary antibody market are developing innovative products such as mutation-specific antibodies to improve diagnostic accuracy, enhance workflow efficiency, and reduce the risk of misdiagnosis. A mutation-specific antibody is designed to bind selectively to a defined antigen variant rather than a broad native antigen population, enabling clinicians to target specific protein mutations with high precision. For example, in February 2023, F. Hoffmann-La Roche AG, a Switzerland based diagnostics and pharmaceutical company, launched the IDH1 R132H (MRQ 67) rabbit monoclonal primary antibody and the ATRX rabbit polyclonal antibody. These products offer high specificity for the IDH1 R132H mutation, are compatible with the BenchMark IHC/ISH platform, and support automated workflows for neuropathology. These antibodies enhance diagnostic precision and workflow efficiency while requiring higher development costs and having narrower target applicability.
In December 2023, Danaher Corporation, a US based biotechnology company, acquired Abcam plc for $5.7 billion. Through this acquisition, Danaher aims to strengthen its position in the life sciences and proteomics market, expanding its portfolio of research reagents, antibodies, and related solutions for drug discovery and diagnostics. Abcam plc is a UK based life sciences company providing primary antibodies for immunology and cancer research.
Major companies operating in the primary antibody market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Danaher Corporation, Johnson & Johnson Services Inc., Fujifilm Holdings Corporation, Agilent Technologies Inc., Becton Dickinson And Company, Regeneron Pharmaceuticals Inc., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Genscript Biotech Corporation, Biocytogen Co. Ltd., Sino Biological Inc., Cell Signaling Technology Inc., Cusabio Biotech Co. Ltd., Proteintech Group Inc., Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Diagnostics Inc., Abnova Corporation, Promab Biotechnologies Inc., Boster Biological Technology Co. Ltd., Biorbyt Ltd., Capralogics Inc.
North America was the largest region in the primary antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the primary antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The primary antibody market consists of sales of antibody reagents, assay kits, detection reagents, antigen-specific probes, and labeling conjugates. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Primary Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on primary antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for primary antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The primary antibody market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Primary Antibodies; Immunoglobulin G (IgG); Immunoglobulin M (IgM); Immunoglobulin A (IgA); Other Isotypes; Secondary Antibodies
2) By Source: Monoclonal Antibodies; Polyclonal Antibodies; Recombinant Antibodies
3) By Technology: Enzyme-Linked Immunosorbent Assay (ELISA); Western Blotting; Immunohistochemistry; Flow Cytometry
4) By Application: Research And Development; Diagnostics; In Vitro Diagnostics; Point Of Care Testing; Therapeutics
5) By End User: Academic And Research Institutions; Pharmaceutical And Biopharmaceutical Companies; Clinical Laboratories; Contract Research Organizations (CROs)
Subsegments:
1) By Primary Antibodies: Mouse Primary Antibodies; Rabbit Primary Antibodies; Goat Primary Antibodies; Human Primary Antibodies; Other Species Primary Antibodies
Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Danaher Corporation; Johnson & Johnson Services Inc.; Fujifilm Holdings Corporation; Agilent Technologies Inc.; Becton Dickinson And Company; Regeneron Pharmaceuticals Inc.; Bio-Techne Corporation; Bio-Rad Laboratories Inc.; Genscript Biotech Corporation; Biocytogen Co. Ltd.; Sino Biological Inc.; Cell Signaling Technology Inc.; Cusabio Biotech Co. Ltd.; Proteintech Group Inc.; Santa Cruz Biotechnology Inc.; Rockland Immunochemicals Inc.; Creative Diagnostics Inc.; Abnova Corporation; Promab Biotechnologies Inc.; Boster Biological Technology Co. Ltd.; Biorbyt Ltd.; Capralogics Inc.
Countries:
Table of Contents
1. Executive Summary
2. Primary Antibody Market Characteristics
3. Primary Antibody Market Trends And Strategies
4. Primary Antibody Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Primary Antibody Growth Analysis And Strategic Analysis Framework
5.1. Global Primary Antibody PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Primary Antibody Market Growth Rate Analysis
5.4. Global Primary Antibody Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Primary Antibody Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Primary Antibody Total Addressable Market (TAM)
6. Primary Antibody Market Segmentation
6.1. Global Primary Antibody Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Primary Antibodies
Immunoglobulin G (IgG)
Immunoglobulin M (IgM)
Immunoglobulin A (IgA)
Other Isotypes
Secondary Antibodies
6.2. Global Primary Antibody Market, Segmentation By Source, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Polyclonal Antibodies
Recombinant Antibodies
6.3. Global Primary Antibody Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme-Linked Immunosorbent Assay (ELISA)
Western Blotting
Immunohistochemistry
Flow Cytometry
6.4. Global Primary Antibody Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Research And Development
Diagnostics
In Vitro Diagnostics
Point Of Care Testing
Therapeutics
6.5. Global Primary Antibody Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Academic And Research Institutions
Pharmaceutical And Biopharmaceutical Companies
Clinical Laboratories
Contract Research Organizations (CROs)
6.6. Global Primary Antibody Market, Sub-Segmentation Of Primary Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mouse Primary Antibodies
Rabbit Primary Antibodies
Goat Primary Antibodies
Human Primary Antibodies
Other Species Primary Antibodies
6.7. Global Primary Antibody Market, Sub-Segmentation Of Immunoglobulin G, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin G1 Subclass
Immunoglobulin G2 Subclass
Immunoglobulin G3 Subclass
Immunoglobulin G4 Subclass
6.8. Global Primary Antibody Market, Sub-Segmentation Of Immunoglobulin M, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pentameric Immunoglobulin M
Monomeric Immunoglobulin M
6.9. Global Primary Antibody Market, Sub-Segmentation Of Immunoglobulin A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin A1 Subclass
Immunoglobulin A2 Subclass
6.10. Global Primary Antibody Market, Sub-Segmentation Of Other Isotypes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunoglobulin D
Immunoglobulin E
6.11. Global Primary Antibody Market, Sub-Segmentation Of Secondary Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Conjugated Secondary Antibodies
Fluorescent Labeled Secondary Antibodies
Biotinylated Secondary Antibodies
Unlabeled Secondary Antibodies
7. Primary Antibody Market Regional And Country Analysis
7.1. Global Primary Antibody Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Primary Antibody Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
